The insulin-like growth factor II (IGF2) gene is exclusively silent at the maternal allele in the mouse as well as in normal human tissues and is expressed at a high level in rhabdomyosarcoma (RMS). We report here that the normally imprinted allele of the IGF2 gene is activated in RMS tumors as well as in one RMS cell line. Since overexpression of IGF2 has been shown to be important in the pathogenesis of RMS, our data suggest that loss of imprinting (LOI) may lead to overexpression of IGF2 and play an important role in the onset of RMS. Furthermore, embryonal RMS usually has loss of heterozygosity (LOH) with paternal disomy of the IGF2 locus. One informative embryonal RMS tumor evaluated in this study was heterozygous at the IGF2 allele and had LOI, raising the possibility that LOI may be the functional equivalent of LOH in this tumor with both events leading to overexpression of IGF2. (J. Clin. Invest. 1994.
Introduction
Rhabdomyosarcoma is the most common soft-tissue sarcoma of childhood and has been associated with overexpression of IGF2 (1) . Furthermore, rhabdomyosarcoma (RMS) 1 is an embryonal tumor that occurs in patients with Beckwith-Wiedemann syndrome (BWS), a fetal overgrowth syndrome associated with paternal disomy of Ip 15 , where the human IGF2 gene has been mapped (2, 3) . Genomic imprinting, a gametespecific modification causing differential expression of the two somatic alleles of a gene, has been considered to play a role in human disease and cancer (4, 5) . Since IGF2 is maternally imprinted in the mouse (6) , it has been suggested that loss of heterozygosity (LOH) with paternal disomy at lpIS may lead to increased expression of IGF2 from two active paternal alleles (7) . It was recently reported that human IGF2 is also maternally imprinted but is biallelically expressed in some Wilms' tumors, another tumor associated with BWS (8, 9) . For these reasons, we examined normal fetal tissue and RMS for imprinting at the IGF2 locus. PCR amplification ofDNA and RNA. PCR amplification of 1 jig of DNA was done using an initial denaturation for 4 min at 940C, then 35 cycles at 940C for 1 min, 550C for 1 min, 720C for 2 min followed by a final extension at 720C for 7 min. Primers used were P1 (5'-CTTGGACYT-GAGTCAAATTGG-3'), P2 (5 '-GGTCGTGCCAAT-TACATTTCA-3') (8, 11) . PCR products were chloroform extracted, ethanol precipitated, digested with Apal, and electrophoresed on a 2% agarose gel. The Apal-undigested and digested alleles were named allele a and allele b, respectively. RNA was transcribed into cDNA using reverse transcriptase (RT) and 0.5 jtg total RNA at 420C for 1 h.
Methods
Subsequent amplification was carried out as above (RT-PCR). To eliminate DNA contamination, total RNA was treated by DNasel at 370C for 2 h before RT-PCR and RT-PCR was performed in the presence (+RT) and absence (-RT) of reverse transcriptase.
Determination ofthe t(2;13)(q35;q14) translocation. The presence of the der(13) fusion transcript produced by the tumor specific t(2;13)(q35;q14) was determined by RT-PCR. This fusion product results from the translocation of 5' PAX3 sequences from chromosome 2 into the DNA binding domain of a forkhead transcription factor on chromosome 13 (12) (13) (14) . The two primers used were PAX1203 (5'-AGACAGCIT-TGTGCCTCCGTC-3') and FKH1507 (5'-CATCATTGCTGTGAG-CCAG-3'), producing a 304 bp fragment spanning the der( 13) breakpoint.
RNA was transcribed into cDNA using reverse transcriptase, and subsequent amplification was carried out using an initial denaturation of 4 min at 94°C, then 39 cycles at 94°C for 1 min, 60°C for 2 min, 72°C for 3 min followed by a final extension at 72°C for 10 min.
Results
Monoallelic expression ofIGF2 in normalfetal tissue. To determine the IGF2 allelic expression in fetal tissue and RMS, we used an ApaI restriction enzyme fragment length polymorphism 231.. (RFLP) in exon 9 of the IGF2 gene ( Fig. 1 A) . DNA and RNA from three normal fetal tissues were amplified by PCR and the products were digested with Apal. Three representative allelotypes are shown in Fig. 1 (Table II and Fig. 2 B) . ( 18) . Since overexpression of IGF2 has been considered to be important in the pathogenesis of RMS (1), loss of imprinting or paternal disomy of the IGF2 locus could contribute to the development of RMS and may play an important role in the pathogenesis of RMS. The Beckwith-Wiedemann syndrome (BWS), which has concurrent high risk for the development of the embryonal tumors RMS, Wilms' tumor, and hepatoblastoma also has been associated with paternal disomy for the 1 lp15.5 region (2, 19) and it has been suggested that the resulting overexpression of IGF2 may be involved in the pathogenesis of this syndrome (7) . Since 
